Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Almost 9 out of 10 hospitalizations for sickle cell disease are for black patients, and most of those patients are younger than 35, new federal data show. Three-quarters of sickle cell patients, who often experience severe pain and racial discrimination, also have government insurance.
The big picture: New treatments for sickle cell have been sparse, despite investments in other rare diseases. But Global Blood Therapeutics hopes to roll out a pill next year, pending federal approval, and Bluebird Bio is aiming to get approval for a sickle cell gene therapy by 2022.